CABA-201 is an experimental therapy being tested in this study. It consists of specially prepared immune cells (T cells) taken from the patient’s own body and modified to target and attack specific cells that have a protein called CD19. This therapy is administered through an intravenous infusion.

Dermatomyositis – This is an inflammatory disease that causes muscle weakness and a distinctive skin rash. The condition often begins with weakness in the muscles closest to the trunk, such as the hips and shoulders. It can also involve skin changes, including red or purple rashes on the face or knuckles. The inflammation can affect various organ systems over time.

Anti-synthetase syndrome – This is a complex condition characterized by a group of symptoms including muscle inflammation and lung issues. It often presents with swollen hands, fever, and lung scarring. The disease involves the immune system attacking specific proteins within the body. It can progress through varying stages of muscle and respiratory involvement.

Immune-mediated necrotizing myopathy – This is a condition where the immune system causes muscle cell death. It leads to progressive and severe muscle weakness, often starting in the proximal muscles. The damage is characterized by significant inflammation and breakdown of muscle tissue. The condition typically worsens as the muscle fibers are destroyed.

Juvenile idiopathic inflammatory myopathy – This is a rare form of inflammatory muscle disease that occurs in children and adolescents. It involves chronic muscle weakness and inflammation caused by an overactive immune system. The disease can impact a child’s physical development and daily activities. It often progresses by gradually reducing muscle strength.